Key Market Indicator:
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 05.04.2023
First Tin Plc
Two new low capex tin mines in Germany and Australia. ESG compliant. High
valuation upside. DFS studies by the end of 2023. Investment decisions by
Q1 2024.
Increasing demand for tin. Tin is an important material when it comes to
the ongoing electrification of the world. At the same time, tin deposits
are limited, especially in Europe. Tin [ … ]
Tue, 04.04.2023
Valneva SE
First Berlin Equity Research has published a research update on Valneva SE
(ISIN: FR0004056851). Analyst Simon Scholes upgraded the stock to BUY but
decreased the price target from EUR 12.00 to EUR 8.90.
Abstract:
2023 guidance for revenue and other income of €220-260m is below the
equivalent 2022 figure of €373.5m. However, over &euro [ … ]
Tue, 04.04.2023
Valneva SE
First Berlin Equity Research has published a research update on Valneva SE
(ISIN: FR0004056851). Analyst Simon Scholes upgraded the stock to BUY but
decreased the price target from EUR 12.00 to EUR 8.90.
Abstract:
2023 guidance for revenue and other income of €220-260m is below the
equivalent 2022 figure of €373.5m. However, over &euro [ … ]
Wed, 29.03.2023
First Tin Plc
“Both projects have demonstrated robust economics at conservative tin
prices.”
First Tin is a company dedicated to ethical, reliable, and sustainable tin
development, featuring cutting-edge, low capex projects located in Germany
and Australia. It is spearheaded by a team of distinguished tin experts,
and is committed to establis [ … ]
Wed, 29.03.2023
First Tin Plc
“Both projects have demonstrated robust economics at conservative tin
prices.”
First Tin is a company dedicated to ethical, reliable, and sustainable tin
development, featuring cutting-edge, low capex projects located in Germany
and Australia. It is spearheaded by a team of distinguished tin experts,
and is committed to establis [ … ]
Mon, 27.03.2023
Smartbroker Holding AG
FY 2022 closed with robust business performance and realignment of fintech
business; Smartbroker relaunch should provide significant revenue and
earnings growth going forward; forecasts and target price lowered; Buy
rating maintained
Business development in the past financial year 2022
On 16 March 2022, Smartbroker Holding AG (Smartb [ … ]
Mon, 27.03.2023
Smartbroker Holding AG
FY 2022 closed with robust business performance and realignment of fintech
business; Smartbroker relaunch should provide significant revenue and
earnings growth going forward; forecasts and target price lowered; Buy
rating maintained
Business development in the past financial year 2022
On 16 March 2022, Smartbroker Holding AG (Smartb [ … ]
Thu, 23.03.2023
Deutsche Rohstoff AG
First Berlin Equity Research has published a research update on Deutsche
Rohstoff AG (ISIN: DE000A0XYG76). Analyst Simon Scholes reiterated his BUY
rating and increased the price target from EUR 34.00 to EUR 38.00.
Abstract:
DRAG's preliminary 2022 results were close to our forecasts. Revenue jumped
126% to €165.4m (FBe: €165.6m; 2021: [ … ]
Thu, 23.03.2023
Deutsche Rohstoff AG
First Berlin Equity Research has published a research update on Deutsche
Rohstoff AG (ISIN: DE000A0XYG76). Analyst Simon Scholes reiterated his BUY
rating and increased the price target from EUR 34.00 to EUR 38.00.
Abstract:
DRAG's preliminary 2022 results were close to our forecasts. Revenue jumped
126% to €165.4m (FBe: €165.6m; 2021: [ … ]
Thu, 23.03.2023
Haemato AG
First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und senkt das Kursziel von EUR 35,00 auf EUR 33,00.
Zusammenfassung:
Wir aktualisieren unsere Prognosen, um den Änderungen des deutschen
Arzneimittelpreis- und Erstattungsgeset [ … ]